ArticleJournal of pharmaceutical and biomedical analysis2011
Effective electrophoretic mobilities and charges of anti-VEGF proteins determined by capillary zone electrophoresis.
Article in Journal of pharmaceutical and biomedical analysis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 60 citations in OpenAlex.
- Vitrectomy Status Alters Early Intravitreal Drug Distribution: An Ex Vivo PET-CT Study.Investigative ophthalmology & visual science · 2026Article
- Oligoarginine peptide structure and its effect on cell penetration in ocular drug delivery.Heliyon · 2024Article
- Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits.Pharmaceutical research · 2024Article
- Application of iontophoresis in ophthalmic practice: an innovative strategy to deliver drugs into the eye.Drug delivery · 2023Review
- Article
- Development and Biophysical Characterization of a Humanized FSH-Blocking Monoclonal Antibody Therapeutic Formulated at an Ultra-High Concentration.bioRxiv : the preprint server for biology · 2023Article
- Ocular Delivery of Therapeutic Proteins: A Review.Pharmaceutics · 2023Review
- Electromotive Enhanced Drug Administration in Oncology: Principles, Evidence, Current and Emerging Applications.Cancers · 2022Review
- Hyaluronic Acid-PEG-Based Diels-AlderBiomacromolecules · 2022Article
- Topical Drug Delivery to the Posterior Segment of the Eye.Pharmaceutics · 2022Review
- Article
- Electroblotting through a tryptic membrane for LC-MS/MS analysis of proteins separated in electrophoretic gels.The Analyst · 2020Article
- Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2020Article
- Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration.Pharmaceutics · 2019Review
- Sustained delivery of anti-VEGF from injectable hydrogel systems provides a prolonged decrease of endothelial cell proliferation and angiogenesisRSC advances · 2018Article
- Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab.Scientific reports · 2017Article
- Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy.Pharmaceutical research · 2016Article
- One-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study.Translational vision science & technology · 2014Article
- Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab.Journal of pharmaceutical sciences · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Macromolecules such as therapeutic proteins currently serve an important role in the treatment of eye diseases such as wet age-related macular degeneration and diabetic retinopathy. Particularly, bevacizumab and ranibizumab have been shown to be effective in the treatment of these diseases. Iontophoresis can be employed to enhance ocular delivery of these macromolecules, but the lack of information on the properties of these macromolecules has hindered its development. The objectives of the present study were to determine the effective electrophoretic mobilities and charges of bevacizumab, ranibizumab, and model compound polystyrene sulfonate (PSS) using capillary zone electrophoresis. Salicylate, lidocaine, and bovine serum albumin (BSA), which have known electrophoretic mobilities in the literature, were also studied to validate the present technique. The hydrodynamic radii and diffusion coefficients of BSA, bevacizumab, ranibizumab, and PSS were measured by dynamic light scattering. The effective charges were calculated using the Einstein relation between diffusion coefficient and electrophoretic mobility and the Henry equation. The results show that bevacizumab and ranibizumab have low electrophoretic mobilities and are net negatively charged in phosphate buffered saline (PBS) of pH 7.4 and 0.16M ionic strength. PSS has high negative charge but the electrophoretic mobility in PBS is lower than that expected from the polymer structure. The present study demonstrated that capillary electrophoresis could be used to characterize the mobility and charge properties of drug candidates in the development of iontophoretic drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.